jc
@JadChahoud
Genitourinary Medical Oncologist @MoffittNews @MoffittResearch
🚨 Common sense in HCC trials: Is PFS always a meaningful endpoint? Not really. If progression-free survival doesn’t translate into better quality of life, then it’s not a good endpoint — at least, not for all patients. @oncodaily @achoHematoYOnco
The Malouf Lab at IGBMC (Strasbourg, France) is recruiting a postdoctoral researcher to join a translational research program focused on rare and treatment-resistant kidney cancers. 🔗 Full details here: igbmc.fr/en/job-offers/… Let’s build something meaningful @SPBassociation
Bravo @JournalCancer and @AmericanCancer on this fantastic choice. @DrRanaMcKay is the real deal and the total package. cc: @UCSDCancer
Please join us in welcoming @DrRanaMcKay as our new Section Editor for Genitourinary Disease! Dr. McKay is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include precision medicine and biomarker development. @OncoAlert
Sign up for free to read our latest feature on cellular therapies in solid tumors! We spoke with @KayvanZarrabi, @DrBetofMDPhD, @JadChahoud, and @AnnaSureda5 to discuss the current and future status of several agents. #oncology #CART
Published today our new LAG-3 paper @CellCellPress. My group #JasperDu #JiaYou and collaborators revealed a key role of TCR proximity in LAG-3’s inhibitory function and developed LAG-3/TCR BiTS to effectively inhibit LAG-3+ T cells. dlvr.it/TLhkv7
#STELLAR002 Trial: Zanzalintinib combo shows promise in clear cell #RCC. @JadChahoud @MoffittNews sits with @PBarataMD @caseccc discussing zanzalintinib combinations in first-line clear cell renal cell carcinoma. Dr. Chahoud explains the study's design, testing two arms:…
I had the pleasure of meeting w/ @ASCO staff last week in which I introduced my presidential theme for 2025-2026: "The Science and Practice of Translation: Improving Cancer Outcomes Worldwide." Excited to roll this out over the course of the year, and of course, at #ASCO26!
Dr. Ohlsen describes what it’s like to be an early-career researcher looking for support in today’s funding landscape. Help support research and vital programs with a gift to our #SummerFund today. brnw.ch/21wUg2n #ConquerCancer
Societie International d'Urologie (SIU) is a urological society with more than 17,000 members from over 130 countries globally. This year, the SIU Congress will be held in Edinburgh from 29th October to 1st November. Registration link: siu-urology.org/congress-2025/…
Honored to lead and participate with Dr. Spiess in our newest manuscript : Management and optimization of chronic renal insufficiency in the setting of kidney cancer: A Systematic Review @onconephsociety @kdjhaveri @ShrutiGkidney @SabineKaram6 @MegSise pubmed.ncbi.nlm.nih.gov/40658472/
📣 Open Call: There is one IKCC Board position open for nomination for 2025: General Board Director. Deadline for applications is 11 August 2025. Find all details at: ikcc.org/call-for-expre…
🚨 Fellowship Applicants 🚨 Visibility matters. Believe it or not, people have landed interviews by having a presence on X. Drop your intro post with info (or create one!) in the replies here. All specialties are welcome. I’ll amplify as many as I can by reposting you. My…
The best part of Hematology/Oncology? You build deep, meaningful relationships with your patients. The hardest part of Hematology/Oncology? You build deep, meaningful relationships with your patients.
@NEJM INAVO120 Trial Highlights in PIK3CA-mutated HR+/HER2- mBC: ✅ OS: 34.0 mo (inavolisib) vs 27.0 mo (placebo) ✅ HR for death: 0.67 (P = 0.02) ✅ ORR: 62.7% vs 28.0% (P < 0.001) ✅ PFS HR: 0.42 ⚠️ AEs: More GI, mucosal with inavolisib #bcsm nejm.org/doi/full/10.10…
Thrilled, honored, and humbled to be selected as a new Sabin fellow @MDAndersonNews! Immensely grateful to the Sabin family for their generous support and inspiring vision to advance innovative cancer research and therapies. Congratulations to all the new fellows— excited for the…
Congratulations to the 2025 Sabin Family Fellows — 10 early career researchers selected for their bold, high-impact cancer research. We thank the Sabin Family Fellowship for their continued support. spr.ly/60154Ibll #EndCancer
Excited to share I’ve been accepted to the 2025 ASCO/AACR Methods in Clinical Cancer Research Workshop in La Jolla, San Diego. Grateful to Dr. Rafee Talukder and Dr. Leo Luznik for being pillars in making this happen. If you’re attending and are on X, let’s connect.
Because AI has the potential to transform clinical care, #AACRai25 will also highlight the need for fairness in research, emphasizing responsible and inclusive implementation to ensure that these powerful tools benefit all patients with cancer.
The AACR Special Conference on Artificial Intelligence and Machine Learning opens this evening with a keynote lecture from Dana Pe’er. The conference will offer a comprehensive exploration of the transformative role of artificial intelligence in oncology. #AACRai25
Very much looking forward to #ESMO25 in the 😎 city of #Berlin! Huge increase in abstract submissions, and the team is currently working hard on putting together the best scientific program for you! Make sure to join us: with my co-chair @DrChoueiri @FAndreMD @NKI_nl @OncoAlert
📣 #ESMO25: The place where oncology leaders meet to explore the future of oncology. Register today! ⏰ Early registration deadline: 16 July 2025 🔗 ow.ly/jysG50Wfv3p
1/5 How reproducible are phase III oncology trials? 📊 With @AlexSherryMD @ErikVanZwet @ebludmir et al. We analyzed 632 RCTs (~496,000 pts). The data offer both reassurance and caution for clinicians and researchers. pubmed.ncbi.nlm.nih.gov/40628175/ 👇#MsaouelLab
We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/blog/houssein-…